Startup
Every investor coverage indicates participated in a round Gene S raised.
| Investor | Rounds | Invested |
|---|---|---|
| Centre for Entrepreneurial Research and Innovation (CERI) | Accelerator | - |
| Western Australian government | Accelerator | - |
Investors whose own portfolio pages list Gene S, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Purpose Ventures | its portfolio page ↗ |
Companies Gene S acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Gene S. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A new precision-medicine company formed by Perth's Syngenis Labs, a research institute and two scientists has bought Gene S, maker of the Rosa pharmacogenomics tool; no price was disclosed.
WA VC fund Purpose Ventures has taken on genetic testing startup Gene S as its fourth investment; earlier 2023 backing of PlanCare, Paperly and IDEAcademy is recalled, and the fund's $45m size noted.
WA's New Industries Fund is backing 34 home-grown ventures with over $643,000 in Innovation Booster Grants, most receiving up to $20,000 for commercialisation support, with four funded via a life sciences stream.
CERI has named the first recipients of its CERI Start fund, with seven startups sharing $50,000 in equity-free micro-seed funding for product development and early commercialisation.